Selcia

Selcia is a chemistry based CRO offering integrated drug discovery and 14C radiolabelling services. Selcia provides high quality radiochemicals for preclinical and clinical ADME, mass balance and microdosing studies. Selcia’s expertise in capillary electrophoresis (CE) offers clients the benefits of a powerful and proven technology applied to drug discovery and fragment based screening, on a wide variety of targets.

Selcia Discovery offers integrated drug discovery services including screening biology, medicinal chemistry, ADME/PK and in vivo PK work. Selcia has a track record of delivering viable drug candidates against its partners’ biological targets. Selcia's CE technology can be used with a broad range of targets to generate binding data under physiological conditions without modification of the protein. This high-resolution separation technique is able to detect both high and low affinity molecular interactions. Selcia's proprietary fragment screening, CEfrag is a powerful application of this technology.

Selcia Radiolabelling is the leading independent custom radiosynthesis laboratory delivering high purity 14C radiolabelled compounds for preclinical and clinical ADME studies. Selcia offers 14C radiosynthesis, including GMP 14C-API for clinical trials, synthesis of stable labelled compounds, radiochemical storage, 14C stock management, repurification, GLP certification and GLP NMR services, synthesis of process impurities and metabolites.

Specialties

Medicinal chemistry, Integrated drug discovery, Carbon-14 radiochemistry, radiolabelling, radiolabeling, radiochemicals, Fragment based screening using capillary electrophoresis, Drug discovery screening using capillary electrophoresis